OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.81 EUR 3.57%
Market Cap: 127.5m EUR

OSE Immunotherapeutics SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OSE Immunotherapeutics SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Total Liabilities & Equity
€140.9m
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Total Liabilities & Equity
€500m
CAGR 3-Years
-15%
CAGR 5-Years
14%
CAGR 10-Years
8%
Nanobiotix SA
PAR:NANO
Total Liabilities & Equity
€86.7m
CAGR 3-Years
-11%
CAGR 5-Years
3%
CAGR 10-Years
11%
G
Genfit SA
PAR:GNFT
Total Liabilities & Equity
€194.8m
CAGR 3-Years
13%
CAGR 5-Years
-10%
CAGR 10-Years
10%
Inventiva SA
PAR:IVA
Total Liabilities & Equity
€39.4m
CAGR 3-Years
-31%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Total Liabilities & Equity
€313.8m
CAGR 3-Years
20%
CAGR 5-Years
34%
CAGR 10-Years
22%

OSE Immunotherapeutics SA
Glance View

Market Cap
126.4m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.9 EUR
Undervaluation 26%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Total Liabilities & Equity?
Total Liabilities & Equity
140.9m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Total Liabilities & Equity amounts to 140.9m EUR.

What is OSE Immunotherapeutics SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
8%

Over the last year, the Total Liabilities & Equity growth was 75%. The average annual Total Liabilities & Equity growth rates for OSE Immunotherapeutics SA have been 13% over the past three years , 8% over the past five years .

Back to Top